

Benralizumab for treating severe eosinophilic asthma – Appraisal Consultation Document

Errata

The Appraisal Consultation Document (ACD) issued to consultees and commentators on 03 May 2018, and published on the NICE web site on 11 May 2018, contained 2 errors (see table). The web version of the ACD has been corrected as of 15 May 2018.

Location in report	Original text	Corrected text
Section 3.8, Page 11	Without the MUSCA data, the results favoured mepolizumab but the reverse was the case if MUSCA data were included.	Without the MUSCA data, the results favoured benralizumab but the reverse was the case if MUSCA data were included.”
Section 3.8, Page 11	The relative effect was assumed to apply to the subgroup of people with a blood eosinophil count of 300 cells per microlitre or more, who had 3 or more exacerbations”	The relative effect was assumed to apply to the subgroup of people with a blood eosinophil count of 300 cells per microlitre or more, who had 4 or more exacerbations
